Immunization

Bivalent mRNA and protein-based fourth doses produce comparable protection against Omicron JN.1 infection over 12 months.

Nine pharmacy organizations state that the revised charter overemphasizes vaccine risk and could delay recommendations pharmacists rely on for scope of practice and insurance coverage.

A newly published review traces chikungunya's re-emergence to a record 2025 outbreak in China, and 2 FDA-approved vaccines shape prevention strategy for pharmacists.

A new surveillance study shows pneumococcal vaccine shifts cut key antibiotic resistance for invasive pneumococcal disease.

Researchers assess the impact of various pneumococcal conjugate vaccines since the introduction of immunization programming.

CDC-led VISION interim data show 2025-2026 COVID-19 shots cut adult emergency room visits and hospitalizations.

Updated charter shifts committee governance to the CDC director and drops fixed meeting schedules.

Coadministering COVID-19 and influenza vaccines did not raise the 90-day risk of serious or clinically meaningful adverse events.

As cases approach the full-year 2025 total, declining vaccination coverage and vaccine hesitancy put pharmacists on the front lines of a public health crisis.

AAP challenges HHS as ACIP stalls, leaving pharmacists and health care in limbo on vaccine coverage and respiratory recommendations.

Retracted vaccine-autism study exposes statistical flaws, reigniting hepatitis B birth-dose debate and highlighting why pharmacists must rely on evidence-based data.

FDA advisors back Moderna’s mRNA flu shot for older adults, hinting at a potential egg-free option for 2026–2027.

The pneumococcal vaccine is approved for protection against 21 serotypes in adults over 18 and children between 2 and 17 at high risk of disease.

Pharmacy technicians expand vaccine access by handling inventory, billing, screening, and even injections.

With continued reports of gradually waning efficacy among pneumococcal vaccines, researchers look toward vaccine effectiveness among patients aged 18 to 64 years.

This schedule arrives at a time of unprecedented friction between leading medical societies and federal health agencies.

Alongside malnutrition instances and measles cases, researchers review pneumonia disease burden and immune vulnerability across high-risk pediatric groups.

BA.3.2 variant spreads globally, testing vaccine matches as the FDA backs XFG immunizations.

Federal court blocks abrupt childhood vaccine schedule changes, raising insurance and liability uncertainty as pharmacies navigate shifting guidance and growing parent hesitancy.

The executive order calls to realign core childhood vaccine recommendations with scientific evidence and best practices of peer, developed nations.

Exploring both the PCV20 and PCV21 pneumococcal vaccines, researchers compare the differences in immune effects between patients at 50 and 65 years old.

In a meta-analysis conducted between 2013 and 2023, researchers explore the overall impact of interventions geared toward boosting pneumococcal vaccination rates.

Across rural US community pharmacies, researchers explore the common barriers and facilitators to pneumococcal vaccine uptake.

A new 25-valent pediatric pneumococcal vaccine enters phase 3 after strong data, aiming for broader coverage and improved serotype 3 protection.

Preventing pneumococcal disease remains a cornerstone of public health, yet the strategy for protection is increasingly individualized and complex.